 Biosimilar drugs are becoming increasingly popular as a cost-effective alternative to original biologic medications. They are similar to the original drug in terms of structure and function, but differ slightly in terms of chemical composition or manufacturing process. Despite their similarity, there are still some differences between biosimilars and originators, which can lead to uncertainty regarding their safety and efficacy. In order to ensure patient safety, it is important for healthcare professionals to understand the differences between biosimilars and originators, and to be able to make informed decisions when prescribing them. This article provides an overview of the current guidelines on the use of biosimilars in rheumatoid arthritis and related conditions. This article was authored by Daniella Murato, Angela Cerebelli, and Piercarlo Sartzi-Patani.